Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Table 1 MTS transition schedule and final dosages by ADHD medication at baseline

Baseline ADHD Medication	Baseline Dose, mg/d	Converted MTS Dose, mg/9 hour	Final MTS Dose Subjects, n (%)
			10 mg (n = 23)	15 mg (n = 30)	20 mg (n = 52)	30 mg (n = 59)
Concerta^® (n = 112)	18 (n = 13)	10	5 (38.5)	5 (38.5)	3 (23.1)	0
	27 (n = 24)	15	1 (4.2)	9 (37.5)	10 (41.7)	4 (16.7)
	36 (n = 46)	20	0	1 (2.2)	26 (56.5)	19 (41.3)
	45 (n = 2)	20	0	0	1 (50.0)	1 (50.0)
	54 (n = 27)	30	0	0	1 (3.7)	26 (96.3)
Ritalin LA^® (n = 26)	10 (n = 3)	10	2 (66.7)	1 (33.3)	0	0
	20 (n = 9)	10	4 (44.4)	3 (33.3)	2 (22.2)	0
	30 (n = 9)	15	0	3 (33.3)	5 (55.6)	1 (11.1)
	40 (n = 2)	20	0	1 (50.0)	0	1 (50.0)
	50 (n = 3)	30	0	0	0	3 (100.0)
Metadate CD^® (n = 26)	10 (n = 1)	10	1 (100.0)	0	0	0
	15 (n = 1)	10	1 (100.0)	0	0	0
	20 (n = 12)	10	8 (66.7)	4 (33.3)	0	0
	30 (n = 7)	15	1 (14.3)	3 (42.9)	1 (14.3)	2 (28.6)
	40 (n = 3)	20	0	0	2 (66.7)	1 (33.3)
	50 (n = 2)	30	0	0	1 (50.0)	1 (50.0)

MTS = methylphenidate transdermal system; ADHD = attention-deficit/hyperactivity disorder.

ISSN: 1753-2000